Transmedics

TMDX

Market cap $4.85B

TMDX gains momentum as OCS technology, a robust pipeline and strong Q3 results fuel growth, though gross margin pressure tempers the outlook.

I see a clear path for TransMedics to deliver at least mid-20% revenue growth in 2026, with upside as year-over-year comparisons get easier. I believe operating margins will continue to expand as scale improves and the bulk of U.S. infrastructure spending moves into the rearview mirror. I expect operating profits to grow faster than revenue, setting up improving free cash flow as 2026 progresses.

TransMedics Group, Inc. (TMDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ANDOVER, Mass., Jan. 12, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing of a long-term lease for its new global headquarters at Assembly Innovation Park in Somerville, as well as the acquisition of the adjacent land parcel to create an integrated TransMedics campus environment.

TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.

ANDOVER, Mass., Dec. 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 44th Annual J.P.

Investors look for heavily shorted stocks either to bet on a further decline in the company's value or to profit from a potential short squeeze.

These healthcare growth stocks are profitable and revenue is growing at a double-digit pace. Intuitive Surgical is the top global player in the field of robotic surgery.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

ANDOVER, Mass. , Dec. 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 22, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 6,333 shares of its common stock and an aggregate of 4,205 restricted stock units to 5 employees, each as a material inducement for each employee's entry into employment with TransMedics.